See every side of every news story

Published 3 days ago • loading... • Updated 3 days ago

SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML

Summary by Clinical Trials Arena

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50%The post SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML appeared first on Clinical Trials Arena.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

Clinical Trials Arena

SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50%The post SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML appeared first on Clinical Trials Arena.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated3 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in 3 days ago on Wednesday, July 16, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics